---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001176"
form_type: "8-K"
ticker: "XAIR"
cik: "0001641631"
company_name: "Beyond Air, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:06:58.074236+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Beyond Air subsidiary NeuroNOS secures $2M initial funding for autism therapy development

## Summary
- NeuroNOS raised $2M initial equity from private investors as part of a larger round up to $5M total.
- Proceeds will accelerate preclinical development of a small-molecule drug targeting nitric oxide dysregulation in autism.
- First-in-human clinical trial anticipated to begin in 2026; formulation optimization for subcutaneous injection underway.
- After initial close, Beyond Air Ireland holds ~88% of NeuroNOS; would fall to ~75% if all $5M shares sold.
- Drug stems from Hebrew University research showing NO inhibition improves autism phenotypes in animal models.

## SEC filing metadata
- accession: 0001641172-25-001176
- form_type: 8-K
- ticker: XAIR
- cik: 0001641631
- company_name: Beyond Air, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641631/000164117225001176/0001641172-25-001176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641631/000164117225001176/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001176
- JSON: https://secwatch.observer/filing/0001641172-25-001176.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.